XML 30 R20.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Information | 3 Months Ended
--- | ---
Mar. 31, 2023
Segment Reporting [Abstract] |
Segment Information | 14. Segment Information The Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The Company manages its operations through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker uses the revenues and earnings (losses) of the operating segments, among other factors, for performance evaluation and resource allocation among these segments. The reportable segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development. Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. Biobanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, asset information is not reported by operating segment. Total assets were $362,416 and $401,066 as of March 31, 2023 and December 31, 2022, respectively. Financial information by segment for the three months ended March 31, 2023 and 2022 is as follows:
|  | Three Months Ended March 31, 2023 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net sales |  | $ | - |  |  | $ | 1,357 |  |  | $ | 2,578 |  |  | $ | - |  |  | $ | 3,935 |
Gross profit |  |  | - |  |  |  | 885 |  |  |  | 1,047 |  |  |  | - |  |  |  | 1,932 |
Direct expenses |  |  | 40,162 |  |  |  | 344 |  |  |  | 3,009 |  |  |  | 11,155 |  |  |  | 54,670 |
Segment contribution |  | $ | (40,162 | ) |  | $ | 541 |  |  | $ | (1,962 | ) |  |  | (11,155 | ) |  |  | (52,738 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 11,132 |  | (a) |  | 11,132 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (63,870 | )
(a) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  | (18,932 | ) |  |  |
Change in fair value of contingent stock consideration |  |  |  |  |  |  |  |  |  |  |  | (110 | ) |  |  |
Goodwill impairment |  |  |  |  |  |  |  |  |  |  |  | 29,633 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 541 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 11,132 |  |  |  |
|  | Three Months Ended March 31, 2022 |
|  | Cell Therapy |  |  | BioBanking |  |  | Degenerative Disease |  |  | Other |  |  | Total |
Net sales |  | $ | - |  |  | $ | 1,283 |  |  | $ | 4,652 |  |  | $ | - |  |  | $ | 5,935 |
Gross profit |  |  | - |  |  |  | 335 |  |  |  | 1,574 |  |  |  | - |  |  |  | 1,909 |
Direct expenses |  |  | 21,213 |  |  |  | 626 |  |  |  | 1,459 |  |  |  | 13,270 |  |  |  | 36,568 |
Segment contribution |  |  | (21,213 | ) |  |  | (291 | ) |  |  | 115 |  |  |  | (13,270 | ) |  |  | (34,659 | )
Indirect expenses |  |  |  |  |  |  |  |  |  |  |  | 6,955 |  | (b) |  | 6,955 |
Loss from operations |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (41,614 | )
(b) Components of other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Change in fair value of contingent consideration liability |  |  |  |  |  |  |  |  |  |  |  | 4,849 |  |  |  |
Change in fair value of contingent stock consideration |  |  |  |  |  |  |  |  |  |  |  | 1,565 |  |  |  |
Amortization |  |  |  |  |  |  |  |  |  |  |  | 541 |  |  |  |
Total other |  |  |  |  |  |  |  |  |  |  | $ | 6,955 |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration